VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
On October 8, 2019, VistaGen Therapeutics, Inc. (the “Company”) began utilizing a new corporate presentation, a copy of which is attached to this Current Report on Form 8-K as Exhibit 99.1.
The information in Item 7.01 of this Current Report onForm8-K,including the information set forth in Exhibit99.1, is being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall Exhibit 99.1 filed herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 8.01. Other Events.
On October 8, 2019, the Company issued a press release announcing that the last patient completed dosing in the Company\’s ELEVATE Phase 2 clinical study of AV-101 as an adjunctive treatment with an FDA-approved oral antidepressant for major depressive disorder. The Company remains on track to report top line results of the ELEVATE study before the end of 2019. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.2.
This Current Report on Form 8-K and the exhibit(s) attached hereto may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, (i) statements with respect to the Company\’s plans, objectives, expectations and intentions; and (ii) other statements identified by words such as \”may\”, \”could\”, \”would\”, \”should\”, \”believes\”, \”expects\”, \”anticipates\”, \”estimates\”, \”intends\”, \”plans\” or similar expressions. These statements are based upon the current beliefs and expectations of the Company\’s management and are subject to significant risks and uncertainties.
Item 9.01. Exhibits.
See Exhibit Index.
VistaGen Therapeutics, Inc. Exhibit
To view the full exhibit click
About VistaGen Therapeutics, Inc. (NASDAQ:VTGN)
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs.
An ad to help with our costs